Jan. 21 (UPI) -- The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday. Advertisement MDD is one of the most common psychiatric disorders, with an estimated 21 million adults in the United States living with the disease, according to